VIVUS (Nasdaq: VVUS) narrowed fourth quarter losses to 17 cents per share from 56 cents per share a year earlier but concerns about sales of its obesity treatment Qsymia weighed down the stock price 89 cents to close at $5.86.
Qsymia Sales Concerns Weigh Down VIVUS
February 25, 2014 at 17:46 PM EST
